Ironwood Pharma (IRWD) Tops Q1 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/23/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
- One killed, three injured when man attacks Swedish school with sword
Mizuho Securities Raises Price Target on Ironwood Pharma (IRWD) as Milestone Drives 1Q Beat
May 10, 2016 6:43 AM EDTMizuho Securities reiterated a Buy rating on Ironwood Pharmaceuticals (NASDAQ: IRWD), and raised the price target to $16.00 (from $15.00), following the company's 1Q earnings report. IRWD reported $66M in revenues and loss of ($0.08) per share, both ahead of consensus estimates of $53.6M and ($0.14). The beat can be... More
